Does Rallies show 13F holders for ACRV?

Yes. Rallies tracks hedge fund and 13F ownership data for ACRV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACRV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACRV. It does not provide personalized investment advice.

ACRV (Acrivon Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Acrivon Therapeutics, Inc. Common Stock (ACRV) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRV trades at $1.81 with a market cap of $70.62M and a P/E ratio of -0.85. ACRV moved +10.00% today. Year to date, ACRV is -23.14%; over the trailing twelve months it is +40.80%. Its 52-week range spans $1.05 to $8.74. Analyst consensus is strong buy with an average price target of $11.20. Rallies surfaces ACRV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACRV stock?

Hedge funds tracked by Rallies that own ACRV include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acrivon Therapeutics, Inc. Common Stock.

ACRV Key Metrics

Key financial metrics for ACRV
Metric	Value
Price	$1.81
Market Cap	$70.62M
P/E Ratio	-0.85
EPS	$-2.02
Dividend Yield	0.00%
52-Week High	$8.74
52-Week Low	$1.05
Volume	76
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-77.91M
Gross Margin	0.00%

Top Hedge Funds Holding ACRV

Panagora Asset holds 33.81K shares of ACRV, changed +0.00% as of Mar 31, 2026.

Latest ACRV News

Acrivon Preclinical Data Showcase ACR-368 and ACR-2316 Synergies with PD-L1 and ADC Topo1 — Apr 17, 2026
Acrivon’s ACR-368 Shows 52% Response Rate, Expands Trials with Two New Cohorts — Mar 19, 2026
Acrivon’s ACR-368 Shows Potent Synergy with Topo1 ADCs; ACR-2316 Yields Durable Tumor Regression — Mar 17, 2026
Acrivon Therapeutics Reports 52% ORR and 74% DCR in Serous Endometrial Cancer — Feb 27, 2026
Acrivon Launches CLIA-Certified Watertown Lab, Targets H1 2026 Operations — Feb 18, 2026

Recent ACRV Insider Trades

Blume-Jensen Peter bought 49.00K (~$82.12K) on Jan 14, 2026.
Levy Adam D. bought 8.83K (~$15.00K) on Jan 14, 2026.
Devroe Eric bought 10.00K (~$17.22K) on Jan 13, 2026.

ACRV Analyst Consensus

6 analysts cover ACRV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.20.

Common questions about ACRV

Who owns ACRV stock?: Hedge funds tracked by Rallies that own ACRV include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Acrivon Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ACRV?: Yes. Rallies tracks hedge fund and 13F ownership data for ACRV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACRV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACRV. It does not provide personalized investment advice.